Inovio Pharmaceuticals Inc
F:GBM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Inovio Pharmaceuticals Inc
F:GBM
|
US |
|
W
|
Wynn Resorts Ltd
DUS:WYR
|
US |
|
Abb Ltd
LSE:0NX2
|
CH |
|
G
|
Golden Metal Resources PLC
LSE:GMET
|
UK |
|
Orexo AB
STO:ORX
|
SE |
|
C
|
China Reinsurance Group Corp
SWB:C53
|
CN |
Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals is a biotechnology company that develops DNA-based medicines, especially vaccines and immunotherapies. Its core idea is to design circular DNA plasmids that tell the body’s cells to make specific proteins, which can train the immune system to fight infections or attack cancer cells. The company also built a delivery device called CELLECTRA, which helps push that DNA into cells so the treatment can work as intended. Inovio focuses on diseases where the immune system can be taught to recognize a clear target, such as human papillomavirus, certain infectious diseases, and some cancers. It does not sell a broad portfolio of commercial drugs; instead, it earns money mainly through research partnerships, grants, and other collaboration-related payments while it advances its own drug candidates through development. That makes it more of a platform-stage biotech than a traditional drugmaker with established product sales. What makes Inovio different is its combination of a DNA medicine design platform and a built-in delivery system. Many biotech companies can design a vaccine or therapy, but Inovio’s business depends on both creating the DNA sequence and getting it into cells with its electroporation device. In practice, it sits early in the drug development chain, turning lab-designed immune targets into treatment candidates that may later be licensed, partnered, or approved if development succeeds.
Inovio Pharmaceuticals is a biotechnology company that develops DNA-based medicines, especially vaccines and immunotherapies. Its core idea is to design circular DNA plasmids that tell the body’s cells to make specific proteins, which can train the immune system to fight infections or attack cancer cells. The company also built a delivery device called CELLECTRA, which helps push that DNA into cells so the treatment can work as intended.
Inovio focuses on diseases where the immune system can be taught to recognize a clear target, such as human papillomavirus, certain infectious diseases, and some cancers. It does not sell a broad portfolio of commercial drugs; instead, it earns money mainly through research partnerships, grants, and other collaboration-related payments while it advances its own drug candidates through development. That makes it more of a platform-stage biotech than a traditional drugmaker with established product sales.
What makes Inovio different is its combination of a DNA medicine design platform and a built-in delivery system. Many biotech companies can design a vaccine or therapy, but Inovio’s business depends on both creating the DNA sequence and getting it into cells with its electroporation device. In practice, it sits early in the drug development chain, turning lab-designed immune targets into treatment candidates that may later be licensed, partnered, or approved if development succeeds.
INO-3107 progress: Inovio said the FDA’s mid-cycle review of the BLA raised no new significant issues, and the company still expects the key PDUFA target date of October 30, 2026.
Accelerated approval: Management said it remains in discussion with the FDA about whether INO-3107 qualifies for accelerated approval, with the main debate centered on whether the drug offers a meaningful therapeutic benefit over the approved product.
Commercial prep: Inovio is building launch readiness for a potential 2026 U.S. approval and plans to commercialize INO-3107 itself with support from outside partners.
Cash runway: The company ended Q1 with $37.7 million in cash, cash equivalents and short-term investments, and said an April equity raise added about $16 million in net proceeds, extending runway into Q1 2027.
Pipeline: Beyond INO-3107, Inovio highlighted a new GBM collaboration with Akeso and Dana-Farber plus progress on its DPROT platform in hemophilia A, Fabry disease and hypophosphatasia.
Competitive view: Management acknowledged the launch of PAPZIMEOS but argued INO-3107 could still be differentiated on efficacy, tolerability and a simpler regimen, with most of the market still available by the time it launches.
